secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2025-11-03T23:59:59+00:00
Accession:  0001619856-25-000065
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Caribou reports positive vispa-cel phase 1 data: 82% ORR, 64% CR in 2L LBCL; cash ~$159.2M
--------------------------------------------------------------------------------

- Vispa-cel confirmatory cohort (N=22): 82% ORR, 64% CR rate, 51% 12-month PFS in 2L LBCL.
- Optimized profile cohort (N=35): 86% ORR, 63% CR rate, 53% 12-month PFS; median follow-up 11.8 months.
- CB-011 (BCMA) dose escalation: 92% ORR, 75% CR/sCR at RDE (450M cells) in BCMA-naïve r/r MM; dose expansion by end 2025.
- Planned pivotal phase 3 for vispa-cel in 2L LBCL: FDA recommends randomized controlled trial, ~250 patients, PFS primary endpoint.
- Preliminary cash, equivalents, and marketable securities as of Sep 30, 2025: approximately $159.2 million.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000065/0001619856-25-000065-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000161985625000065/crbu-20251103.htm
  HTML page:      https://secwatch.observer/filing/0001619856-25-000065

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer